On November 17, Science Corporation announced a $400 million Series D.
Bloomberg and TechCrunch, each citing a person familiar with the deal, reported that the round valued the company at $3.5 billion. The company itself did not disclose a valuation.
Two commercial patients, so far
PRIMA is a chip about 2 millimetres across, implanted beneath the retina, paired with glasses that beam near-infrared light into the eye. It restores central vision for people blinded by late-stage dry age-related macular degeneration.
It received its CE mark in July and went on sale in Germany. According to Bloomberg, the commercial version has so far been implanted in two patients in Germany, with dozens more being scheduled.
Italy, France and the United Kingdom come next. Moorfields Private Eye Hospital in London will serve self-paying patients; the price has not been disclosed.
The technology was not built from scratch inside the company. PRIMA began in Daniel Palanker's lab at Stanford and was developed by Pixium Vision, a French company. After Pixium went into liquidation, Science bought the technology in 2024 and took over the trials it had started.
Three years, 29 more letters
The valuation rests on the PRIMAvera trial. At three years, 18 patients still assessed for vision read on average 29 more letters on an eye chart than before surgery.
Per year, that is about 9.7 letters.
The results were presented at the EURETINA congress in Vienna this year and have not been published in a journal — a shallower level of peer review than a paper.
On a second indication, one Stargardt patient was implanted at Sydney Eye Hospital in May, and the company reported the case in October.
The American route holds 8,000 people
Science is pursuing a Humanitarian Device Exemption from the FDA. That pathway is open only to devices for conditions affecting no more than 8,000 patients a year in the United States.
The trade-off: the company does not have to prove effectiveness to the usual standard, but the device can be used only at facilities overseen by an institutional review board, and profit is limited.
Science says it has received two Humanitarian Use Device designations — one for bilateral advanced geographic atrophy, one for Stargardt disease. CEO Max Hodak told Bloomberg he expects commercial availability in the US in the first half of next year.
That means the American ceiling is set not by demand but by the 8,000-patient line.
Who is pricing this round
The investor list includes returning backers Khosla Ventures and Y Combinator, plus Tenet Healthcare, a US hospital and outpatient surgery operator, and the Ackman Oxman Institute, a research institute set up in August by Bill Ackman and Neri Oxman.
The company did not name a lead investor.
By its own account, Science has raised more than $900 million since 2021. Its March Series C of $230 million carried a $1.5 billion valuation. Eight months later, the mark is 2.3 times higher.
Two commercial patients against $3.5 billion is an extreme ratio in any industry.
What the money is buying
Not surgical volume today — a regulatory path that might be copied. Ophthalmology first, then implants that require opening the skull.
The eye has a clean endpoint: letters on a chart can be counted. It also has a payer, because eye surgery already sits inside insurance catalogues.
The company's second bet is a biohybrid interface that grows engineered neurons onto a device connected to the brain's own circuits. Animal testing is done. Hodak said he hopes to begin human trials within 16 months. The first disease has been chosen but not announced.
If that line works, today's valuation has a foundation.
Why the eye came first
Cortical implants still have to answer a safety question that takes years and a cohort to answer. A subretinal chip answers a narrower one: does the patient read more letters than before.
That narrow question has a commercial advantage. A device that restores reading can be sold to a hospital, billed to a patient, and reviewed by a regulator on a measurable endpoint. The same logic explains why the company can raise at a $3.5 billion mark with two commercial patients: the risk being priced is regulatory, not scientific.
The limit is equally clear. Under a Humanitarian Device Exemption, the US market is capped by the 8,000-patient threshold, and profit is restricted. Growth has to come from Europe and from the second-generation implant.
*Disclaimer: This article is based on publicly available information and is for reference only. It does not constitute investment advice.*